There is no clinically-proven type-specific therapeutic target for the 10% of breast cancer cases that are negative for ER, PR, and HER2, and hence are designated “triplenegative,” and only genotoxic chemotherapy is utilised (Sørlie et al., 2001). This evidence concerns the gene ERBB2 and breast carcinoma.